bioRxiv / medRxiv
open access
CC BY 4.0
ASXL3 truncating patient variants mediate transcriptional gain-of-function and are antisense oligonucleotide-responsive
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Personalized Antisense Oligonucleotide Therapy for A Single Participant With ASXL3 Gene Mutation#890388
- The role of non-coding variants in hereditary cancer syndromes: mechanistic insights and clinical implications.#360784
- Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)#908850
- Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies#1161610
- Mesenchymal stromal cells in the regeneration of radiation-induced organ sequelae: will they make the difference?#235182
Record · ID 471398
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive